FHN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
FHN is a good buy right now for a beginner with a long-term horizon and $50,000-$100,000 to deploy. The setup is supported by improving fundamentals, constructive institutional and congressional buying, and bullish moving averages. While short-term momentum is slightly mixed, the current pre-market price is still near support and the stock appears acceptable to buy now rather than wait for a perfect entry.
Technically, FHN is in a constructive trend because SMA_5 is above SMA_20 and SMA_20 is above SMA_200, which is a bullish alignment. RSI_6 at 44.3 is neutral, so the stock is not overbought. The MACD histogram is slightly negative and expanding, which shows near-term momentum is not fully confirmed. Price at 24.30-24.47 is very close to support at 24.26 and just below the pivot at 24.73, with resistance at 25.20 and 25.49. Overall, the trend is still favorable for a long-term entry.
["Q1 2026 revenue rose 6.56% YoY", "Q1 2026 net income rose 20.66% YoY", "Q1 2026 EPS rose 29.27% YoY", "Hedge funds are buying aggressively, with reported buying up 9532.83% over the last quarter", "Congress members made a net positive signal with 1 purchase and 0 sales in the last 90 days", "News is supportive, including a senior treasury management hire aimed at improving financial management and innovation", "Analyst targets remain clustered around the mid-20s, and several firms still maintain Buy/Overweight views", "Bullish moving average structure supports the longer-term trend"]
["MACD histogram is still negative and worsening, showing short-term momentum weakness", "Several analysts have trimmed price targets recently", "UBS downgraded the stock to Neutral and sees limited upside without a takeover announcement", "RSI is neutral rather than strong, so immediate upside momentum is not forceful", "Similar candlestick pattern analysis suggests only modest near-term upside and some downside probability over the next day and month"]
In Q1 2026, First Horizon showed healthy growth. Revenue increased to $796 million, up 6.56% year over year. Net income increased to $257 million, up 20.66% YoY, and EPS rose to $0.53, up 29.27% YoY. This latest quarter season indicates improving profitability and solid earnings momentum, which is supportive for a long-term investor.
Analyst sentiment is mixed but still reasonably constructive. Recent target cuts from Keefe Bruyette, BofA, Barclays, Evercore ISI, JPMorgan, Truist, and UBS show some caution on valuation and macro risks, while Citi still rates it Buy and Barclays keeps Overweight. The main Wall Street pros view is that loan growth and net interest income trends look strong, and profitability outlook is solid. The main cons view is limited upside without a takeover and some uncertainty around credit, rates, and broader bank-sector pressure. Overall, analysts are cautious but not bearish.
